Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus Bevacizumab in Mucosal Melanoma
NCT04091217Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2019
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in mucosal melanoma (MM), sponsored by Roche. Primary endpoint: Objective Response Rate at 32 months. Started Nov 2019; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT04091217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091217.